Quick Answer
Allogene Therapeutics, Inc. reported Stockholders Equity of $292.54 million for fiscal year 2025.
Allogene Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $292.54M | -30.7% |
| 2024 | $422.18M | -17.6% |
| 2023 | $512.23M | -11.8% |
| 2023 | $580.63M | -6.6% |
| 2023 | $621.41M | +5.0% |
| 2023 | $592.01M | -11.2% |
| 2022 | $666.88M | -10.3% |
| 2022 | $743.40M | -7.8% |
| 2022 | $806.48M | -6.8% |
| 2022 | $865.27M | -6.5% |
| 2021 | $925.20M | -8.7% |
| 2020 | $1.01B | +61.1% |
| 2019 | $629.02M | -10.5% |
| 2018 | $703.16M | +35158300.0% |
| 2017 | -$2.0K | — |
| 2017 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $315.33M | -32.0% | -8.5% |
| June 30, 2025 | $344.56M | -33.1% | -10.6% |
| March 31, 2025 | $385.39M | -16.5% | -8.7% |
| December 31, 2024 | $422.18M | -17.6% | -9.0% |
| September 30, 2024 | $463.75M | -20.1% | -10.0% |
| June 30, 2024 | $515.04M | -17.1% | +11.6% |
| March 31, 2024 | $461.37M | -22.1% | -9.9% |
| December 31, 2023 | $512.23M | -23.2% | -11.8% |
- Allogene Therapeutics, Inc. showed a decrease of -30.7% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Allogene Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: